BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will present an overview of the company at the Solebury Trout Class of 2018 Biotech IPOs Investor Day on Friday, April 26, 2019, at 2:30 p.m. ET in New York City. The conference is hosted by Davis Polk and BMO Capital Markets.
A live webcast of the presentation will be available on the Investors section of the Gamida Cell website, www.gamida-cell.com, and will be available for at least 30 days following the event.
About Gamida Cell
Gamida Cell is a clinical-stage
biopharmaceutical company committed to developing advanced cell
therapies with the potential to cure blood cancers and rare, serious
hematologic diseases. We are leveraging our proprietary
nicotinamide-based, or NAM-based, cell expansion technology to develop
product candidates designed to address the limitations of cell
therapies. For additional information, please visit www.gamida-cell.com.